Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses

Neuromyelitis Optica Clinical Trial

— A1AT for NMO  

Official title:

A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02087813
• Other study ID #: IRB-27176
• Status: Withdrawn
• Phase: Phase 1
• Start date: March 2014

Study information

• Verified date: April 2019
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Neuromyelitis Optica (NMO) is a rare, devastating demyelinating disease of the central nervous system (CNS) that has different causes and treatments from the more common demyelinating disease multiple sclerosis (MS). Current NMO therapies are nonspecific and have varying and often suboptimal benefit. The investigators will evaluate whether use of alpha1-antitrypsin (A1AT, an FDA-approved medication for patients with congenital deficiency of A1AT associated with emphysema) can benefit acute attacks of NMO, improving patient disability and quality of life.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Provide written informed consent.

• Age =18 and = 75 years.

• Diagnosis of NMO or NMO spectrum disorder (NMOSD). The diagnosis of NMO will conform to the 2006 Wingerchuk criteria.1, 2 The diagnosis of NMOSD will include patients with relapsing optic neuritis and aquaporin-4 antibody (AQP4) seropositivity or patients with relapsing longitudinally extensive transverse myelitis and AQP4 seropositivity.2-5 NMO and NMOSD will be collectively referred to as NMO.

• AQP4-antibody positivity.

• Present with an acute NMO attack (see definition below).

• Patients must not have a history of clinically significant infusion reactions with administration of biologic agents.

• If on chronic treatment for NMO, treatment was initiated at least 3 months earlier and medication dose is stable. Additional restrictions will be placed on changes in concomitant symptomatic medications.

• A female subject of childbearing potential must have a negative serum pregnancy test at the screening visit and agree to use a medically reliable method of contraception (e.g., barrier with either spermicide or hormonal contraception) until study completion.

• Agree to answer the questions on the Columbia Suicide Severity Rating Scale at each specified visit.

Exclusion Criteria:

• A woman who is pregnant, breastfeeding, or planning pregnancy.

• If the patient is enrolled in any other experimental trial or on other experimental therapy.

• If the patient has a known IgA deficiency with IgA-antibodies.

• Any medical condition or clinically significant laboratory abnormality that in the Investigator's judgment may affect the patient's ability to safely complete the study.

Acute attack:

• The occurrence of new or worsening neurological symptoms consistent with optic neuritis, transverse myelitis, or a brain lesion that develop acutely (i.e., patients must present within 7 days of symptom onset).

• The symptoms must persist for at least 48 hours, are not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to concomitant medications).

• The symptoms must be accompanied by sensory, motor or visual acuity objective deficits, which must be verified by the examining physician.

• A single episode of a paroxysmal symptom (e.g., tonic spasm) is not a relapse; however, the new onset of multiple occurrences of a paroxysmal symptom over at least 48 hours can be a relapse if accompanied by a new, corresponding objective deficit.

• Sensory symptoms with no change on clinical examination, fatigue, mood change, or bladder or bowel urgency or incontinence will not be sufficient to establish a relapse.

Related Conditions & MeSH terms

• Neuromyelitis Optica

Intervention

Drug:
• Alpha1-antitrypsin

• methylprednisolone
3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.

Locations

Country	Name	City	State
United States	Stanford University	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Suicidality as a Measure of Safety and Tolerability	Columbia Classification Algorithm for Suicide Assessment (C-SSRS).	Screening, Week 1: Day 2, Week 2, 3, 4, 8, 16, and 24.
Other	Serum biomarkers, including cytokines, elastase level, A1AT level, neutrophil elastase activity.		Baseline, Week 1: Day 2, Week 2, 3, 4, 8, 16, and 24.
Other	Cerebral Spinal Fluid (CSF) biomarkers, including neurofilament, GFAP, MBP, neutrophil elastase activity, A1AT level, cytokines.	Lumbar puncture.	Baseline and Week 8
Other	Quality of life as a Measure of Safety and Tolerability	Functional Assessment of Multiple Sclerosis Quality of Life instrument (FAMS).	Baseline, Week 1: Day 2, Week 2, 3, 4, 8, 16, and 24.
Other	Electrocardiogram (ECG) as a Measure of Safety and Tolerability		Baseline, Day 2, and Week 16.
Other	Urinalysis as a Measure of Safety and Tolerability		Baseline, Day 2, and Week 16.
Primary	Mean change in disability from baseline/nadir to week 24 as assessed by Opticospinal Impairment Score (OSIS) subscale.		Baseline, Week 1: Day 2, Week 2, 3, 4, 8, 16, and 24.
Secondary	Mean change in disability from baseline/nadir to week 24 as assessed by Expanded Disability Status Scale (EDSS).		Baseline, Week 1: Day 2, Week 2, 3, 4, 8, 16, and 24.
Secondary	For patients experiencing optic neuritis, mean change in visual acuity from baseline/nadir to week 24 as assessed by Sloan 2.5% low contrast visual acuity chart.		Baseline, Week 1: Day 2, Week 2, 3, 4, 8, 16, and 24.
Secondary	Mean change in retinal nerve fiber layer from baseline/nadir to week 24 as assessed by optical coherence tomography (OCT).		Baseline and Week 24
Secondary	Mean change in length of spinal cord lesion from baseline/nadir to week 24 as assessed by magnetic resonance imaging (MRI) T2 sequences.		Baseline, Week 24